Showing results (271-280 of 375) with videos related to

Sort By:
Pageof 38
Diabetes, Obesity & Metabolism|October 7, 2021
Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled (glycated haemoglobin ≥8%, ≥64 mmol/mol) on two oral antidiabetes drugs: Post hoc analysis of the LixiLan-O randomized trialMelanie J Davies, Julio Rosenstock, Amar Ali, et al.
The British Journal of Dermatology|March 1, 1993
Bullous eruption of systemic lupus erythematosus: a clinicopathological study of four casesN P Burrows, B S Bhogal, M M Black, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|August 4, 2009
Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipidsA L Brackenridge, N Jackson, W Jefferson, et al.
Molecular and Cellular Endocrinology|May 26, 2009
Mammalian epididymal proteomeJean-Louis Dacheux, Clémence Belleannée, Russell Jones, et al.
Blood|February 7, 2001
Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphomaJ J Scarisbrick, S Whittaker, A V Evans, et al.
The Journal of Investigative Dermatology|August 20, 2003
Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvementXin Mao, Zerrin Onadim, Elizabeth A Price, et al.
The Journal of Investigative Dermatology|March 5, 2002
Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndromeJulia J Scarisbrick, Alison J Woolford, Eduardo Calonje, et al.
Diabetes, Obesity & Metabolism|October 18, 2014
Is insulin the most effective injectable antihyperglycaemic therapy?J B Buse, A Peters, D Russell-Jones, et al.
Clinical Endocrinology|April 21, 1999
Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatmentP V Carroll, M Umpleby, E L Alexander, et al.
Diabetes Care|January 3, 2012
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind studyDavid Russell-Jones, Robert M Cuddihy, Markolf Hanefeld, et al.
Pageof 38